SEQUAB Stock Overview
Develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Sequana Medical NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.59 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 0.84 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -75.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| SEQUAB | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | -2.6% |
| 1Y | n/a | -10.1% | 2.7% |
Return vs Industry: Insufficient data to determine how SEQUAB performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how SEQUAB performed against the UK Market.
Price Volatility
| SEQUAB volatility | |
|---|---|
| SEQUAB Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SEQUAB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SEQUAB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 62 | Ian Crosbie | www.sequanamedical.com |
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure. Sequana Medical NV was founded in 2006 and is headquartered in Ghent, Belgium.
Sequana Medical NV Fundamentals Summary
| SEQUAB fundamental statistics | |
|---|---|
| Market cap | €30.31m |
| Earnings (TTM) | -€32.56m |
| Revenue (TTM) | €712.17k |
42.6x
P/S Ratio-0.9x
P/E RatioIs SEQUAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEQUAB income statement (TTM) | |
|---|---|
| Revenue | €712.17k |
| Cost of Revenue | €164.12k |
| Gross Profit | €548.05k |
| Other Expenses | €33.11m |
| Earnings | -€32.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 19, 2024
| Earnings per share (EPS) | -1.07 |
| Gross Margin | 76.95% |
| Net Profit Margin | -4,572.42% |
| Debt/Equity Ratio | -86.2% |
How did SEQUAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/19 11:39 |
| End of Day Share Price | 2024/05/22 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sequana Medical NV is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Roba | Degroof Petercam |
| Yi Chen | H.C. Wainwright & Co. |
| Thomas Vranken | KBC Securities NV |